Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib long-term extension study in B-cell non-Hodgkin lymphomas
NL-OMON43124Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibrutinib in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL) and 2 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Long-term safety and efficacy of PCI-32765. Started Oct 2016; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON43124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43124.